Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Costabel

Showing results (141-150 of 200) with videos related to

Pageof 20
Sort By:
The Lancet. Respiratory Medicine|December 3, 2014
Combination therapy: the future of management for idiopathic pulmonary fibrosis?Wim A Wuyts, Katerina M Antoniou, Keren Borensztajn, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|December 8, 2017
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosisLisa H Lancaster, Joao A de Andrade, Joseph D Zibrak, et al.
Respiratory Medicine|May 10, 2015
Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosisSteven D Nathan, Roland M du Bois, Carlo Albera, et al.
Annals of the Rheumatic Diseases|August 8, 2020
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trialJames R Seibold, Toby M Maher, Kristin B Highland, et al.
Journal of Clinical Medicine|November 28, 2019
Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort StudyChihiro Hirano, Shinichiro Ohshimo, Yasushi Horimasu, et al.
Chest|November 26, 2018
Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary FibrosisSteven D Nathan, Ulrich Costabel, Ian Glaspole, et al.
Lancet (London, England)|July 3, 2009
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trialTalmadge E King, Carlo Albera, Williamson Z Bradford, et al.
Respiration; International Review of Thoracic Diseases|March 1, 2017
Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Disease: Comparison between Biopsy from 1 Segment and Biopsy from 2 Segments - Diagnostic Yield and ComplicationsClaudia Ravaglia, Athol U Wells, Sara Tomassetti, et al.
Orphanet Journal of Rare Diseases|December 19, 2012
KL-6, a Human MUC1 Mucin, as a prognostic marker for diffuse alveolar hemorrhage syndromeYoshiko Kida, Shinichiro Ohshimo, Kohei Ota, et al.
Lancet (London, England)|May 17, 2011
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsPaul W Noble, Carlo Albera, Williamson Z Bradford, et al.
Pageof 20

Showing results (141-150 of 200) with videos related to

Sort By:
Pageof 20
The Lancet. Respiratory Medicine|December 3, 2014
Combination therapy: the future of management for idiopathic pulmonary fibrosis?Wim A Wuyts, Katerina M Antoniou, Keren Borensztajn, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|December 8, 2017
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosisLisa H Lancaster, Joao A de Andrade, Joseph D Zibrak, et al.
Respiratory Medicine|May 10, 2015
Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosisSteven D Nathan, Roland M du Bois, Carlo Albera, et al.
Annals of the Rheumatic Diseases|August 8, 2020
Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trialJames R Seibold, Toby M Maher, Kristin B Highland, et al.
Journal of Clinical Medicine|November 28, 2019
Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort StudyChihiro Hirano, Shinichiro Ohshimo, Yasushi Horimasu, et al.
Chest|November 26, 2018
Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary FibrosisSteven D Nathan, Ulrich Costabel, Ian Glaspole, et al.
Lancet (London, England)|July 3, 2009
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trialTalmadge E King, Carlo Albera, Williamson Z Bradford, et al.
Respiration; International Review of Thoracic Diseases|March 1, 2017
Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Disease: Comparison between Biopsy from 1 Segment and Biopsy from 2 Segments - Diagnostic Yield and ComplicationsClaudia Ravaglia, Athol U Wells, Sara Tomassetti, et al.
Orphanet Journal of Rare Diseases|December 19, 2012
KL-6, a Human MUC1 Mucin, as a prognostic marker for diffuse alveolar hemorrhage syndromeYoshiko Kida, Shinichiro Ohshimo, Kohei Ota, et al.
Lancet (London, England)|May 17, 2011
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsPaul W Noble, Carlo Albera, Williamson Z Bradford, et al.
Pageof 20